What the FDA labels say about taking them together
Aprepitant and colchicine
Colchicine's FDA label (Lodoco) of August 13, 2026 names aprepitant in its drug interactions section; the aprepitant labels PlainMeds reads (3) do not name colchicine. The colchicine label: “Significant increase in colchicine plasma concentration is anticipated.”
Check it at the source: the aprepitant FDA label on DailyMed (effective July 5, 2024, Merck Sharp & Dohme LLC); the colchicine FDA label on DailyMed (effective July 22, 2025, Aurobindo Pharma Limited).
What does the aprepitant label say about colchicine?
Aprepitant's label (effective July 5, 2024) and its 2 other brand-application labels do not name colchicine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (EMEND), NDA021549 (Msd), as published by Merck Sharp & Dohme LLC, effective July 5, 2024 (SPL set 696f9e80-9cae-403b-de9e-078343ce4713), via openFDA; the full label on DailyMed
What does the colchicine label say about aprepitant?
Lodoco label (AGEPHA Pharma USA, LLC, August 13, 2026), drug interactionsDrug class: Moderate CYP3A4 Inhibitors amprenavir aprepitant diltiazem erythromycin fluconazole, fosamprenavir (prodrug of amprenavir) verapamil; Outcome/effect: Significant increase in colchicine plasma concentration is anticipated.; Clinical comment: Monitor patients receiving moderate CYP3A4 inhibitors for signs of colchicine toxicity. Avoid use in patients with existing renal or hepatic impairment [see Warnings and Precautions (5)].
Source: FDA drug label (Lodoco, NDA215727), AGEPHA Pharma USA, LLC, effective August 13, 2026 (SPL set ff06d68f-d65f-d097-e053-6294a90a7e5f), via openFDA
Source: FDA drug label (Colchicine), Aurobindo Pharma Limited, effective July 22, 2025 (SPL set dd93a40f-92ab-47ac-9083-b8a7a0b18ad6), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Aprepitant | Colchicine | |
|---|---|---|
| Labeled for | Nausea and vomiting | Gout |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $46.42 per capsule 40 mg capsule | $0.122 per tablet 0.6 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once